230 related articles for article (PubMed ID: 25000978)
1. Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells.
Alvarez M; Bouchlaka MN; Sckisel GD; Sungur CM; Chen M; Murphy WJ
J Immunol; 2014 Aug; 193(4):1709-16. PubMed ID: 25000978
[TBL] [Abstract][Full Text] [Related]
2. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
Front Immunol; 2020; 11():7. PubMed ID: 32117218
[TBL] [Abstract][Full Text] [Related]
3. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
4. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
5. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.
Rowley J; Monie A; Hung CF; Wu TC
J Immunol; 2008 Dec; 181(12):8237-47. PubMed ID: 19050240
[TBL] [Abstract][Full Text] [Related]
7. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.
Hallett WHD; Ames E; Álvarez M; Barao I; Taylor PA; Blazar BR; Murphy WJ
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1088-1099. PubMed ID: 18804038
[TBL] [Abstract][Full Text] [Related]
9. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
[TBL] [Abstract][Full Text] [Related]
10. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
11. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.
Takaku S; Terabe M; Ambrosino E; Peng J; Lonning S; McPherson JM; Berzofsky JA
Int J Cancer; 2010 Apr; 126(7):1666-74. PubMed ID: 19830696
[TBL] [Abstract][Full Text] [Related]
12. Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells.
Bergmann C; Wild CA; Narwan M; Lotfi R; Lang S; Brandau S
Eur J Immunol; 2011 Dec; 41(12):3564-73. PubMed ID: 21905023
[TBL] [Abstract][Full Text] [Related]
13. Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFNγ-Dependent Tumor Vessel Regression.
Kurebayashi Y; Olkowski CP; Lane KC; Vasalatiy OV; Xu BC; Okada R; Furusawa A; Choyke PL; Kobayashi H; Sato N
Cancer Res; 2021 Jun; 81(11):3092-3104. PubMed ID: 33574087
[TBL] [Abstract][Full Text] [Related]
14. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer.
Smyth MJ; Teng MW; Swann J; Kyparissoudis K; Godfrey DI; Hayakawa Y
J Immunol; 2006 Feb; 176(3):1582-7. PubMed ID: 16424187
[TBL] [Abstract][Full Text] [Related]
15. Murine natural killer cell licensing and regulation by T regulatory cells in viral responses.
Sungur CM; Tang-Feldman YJ; Ames E; Alvarez M; Chen M; Longo DL; Pomeroy C; Murphy WJ
Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7401-6. PubMed ID: 23589894
[TBL] [Abstract][Full Text] [Related]
16. IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells.
Yu P; Bamford RN; Waldmann TA
Eur J Immunol; 2014 Nov; 44(11):3330-41. PubMed ID: 25142300
[TBL] [Abstract][Full Text] [Related]
17. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
[TBL] [Abstract][Full Text] [Related]
18. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice.
Xia Y; Chen B; Shao X; Xiao W; Qian L; Ding Y; Ji M; Gong W
J Immunother; 2014 Jun; 37(5):257-66. PubMed ID: 24810637
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin deficiency suppresses lymphoma growth in mice by modulating NK cells, CD8 T cells, and myeloid-derived suppressor cells.
Han S; Jeong AL; Lee S; Park JS; Kim KD; Choi I; Yoon SR; Lee MS; Lim JS; Han SH; Yoon DY; Yang Y
J Immunol; 2013 May; 190(9):4877-86. PubMed ID: 23530146
[TBL] [Abstract][Full Text] [Related]
20. CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.
Wang LX; Li Y; Yang G; Pang PY; Haley D; Walker EB; Urba WJ; Hu HM
Eur J Immunol; 2010 May; 40(5):1375-85. PubMed ID: 20186876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
